Jehn U, Mezger J
Cancer Treat Rep. 1985 Apr;69(4):445-8.
Sixteen patients in chronic myeloid leukemia blast crisis entered a phase II trial with vindesine and prednisone. Median duration of the chronic phase was 29 months in 13 patients, one previously had polycythemia vera, and two presented with a primary blast crisis. Eleven patients had myeloblastic features, as evidenced by morphology, cytochemistry, and cell surface antigens; three had a mixture of myeloid and lymphoid blast cells with lymphoblastic predominance; one had blast cells which displayed lymphoid characteristics; and one was classified as undifferentiated. Three patients had complete remissions lasting 1 month (myeloid), 3 months (mixed), and 5 months (lymphoid). Eleven patients had minor responses, with a median duration of 3 weeks (eight with myeloid, two with mixed, and one with undifferentiated). Two patients did not respond to vindesine. Leukopenia and thrombocytopenia were severe and prolonged independent of their morphologic or immunologic phenotype.
16例慢性髓性白血病急变期患者进入了一项使用长春地辛和泼尼松的II期试验。13例患者慢性期的中位持续时间为29个月，1例曾患真性红细胞增多症，2例表现为原发性急变期。11例患者具有髓母细胞特征，形态学、细胞化学和细胞表面抗原可证实；3例有髓系和淋巴系原始细胞混合且以淋巴母细胞为主；1例原始细胞表现出淋巴样特征；1例被归类为未分化型。3例患者获得完全缓解，持续时间分别为1个月（髓系）、3个月（混合型）和5个月（淋巴系）。11例患者有轻度反应，中位持续时间为3周（8例髓系、2例混合型和1例未分化型）。2例患者对长春地辛无反应。白细胞减少和血小板减少严重且持续时间长，与它们的形态学或免疫表型无关。
